HER2 in Uterine Serous Carcinoma: Testing platforms and implications for targeted therapy.
Klc TR, Wu S, Wilhite AM, Jones NL, Powell MA, Olawaiye A, Girda E, Brown J, Puechl A, Ali-Fehmi R, Winer IS, Herzog TJ, Korn WM, Erickson BK.
Klc TR, et al. Among authors: erickson bk.
Gynecol Oncol. 2022 Nov;167(2):289-294. doi: 10.1016/j.ygyno.2022.09.006. Epub 2022 Sep 14.
Gynecol Oncol. 2022.
PMID: 36114027